tert-butyl 3-amino-5-methoxy-1H-pyrazole-1-carboxylate | 1065266-85-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl 3-amino-5-methoxy-1H-pyrazole-1-carboxylate
• 英文别名: tert-butyl 3-amino-5-methoxypyrazole-1-carboxylate
• CAS: 1065266-85-4
• 化学式: C₉H₁₅N₃O₃
• 分子量: 213.236
• InChiKey: JHBSZELCARZUPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  79.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-amino-5-methoxy-1H-pyrazole-1-carboxylate 、 2,6-dichloro-N-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]pyrimidin-4-amine 在 tris-(dibenzylideneacetone)dipalladium(0) caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 为溶剂， 以36%的产率得到6-chloro-N4-[(S)-1-(5-fluoropyridin-2-yl)ethyl]-N2-(5-methoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  WO2008/132502

  摘要：

  公开号：
• 作为产物：
  描述：

  5-甲氧基-1H-吡唑-3-胺 、 二碳酸二叔丁酯 在 氢氧化钾 作用下， 以 二氯甲烷 为溶剂， 生成 tert-butyl 3-amino-5-methoxy-1H-pyrazole-1-carboxylate
  参考文献：
  名称：

  WO2008/132502

  摘要：

  公开号：

文献信息

• Discovery of novel Jak2–Stat pathway inhibitors with extended residence time on target
  作者：Huiping Guan、Michelle L. Lamb、Bo Peng、Shan Huang、Nancy DeGrace、Jon Read、Syeed Hussain、Jiaquan Wu、Caroline Rivard、Marat Alimzhanov、Geraldine Bebernitz、Kirsten Bell、Minwei Ye、Michael Zinda、Stephanos Ioannidis

  DOI：10.1016/j.bmcl.2013.02.111

  日期：2013.5

  The discovery of the activating mutation V617F in the JH2 domain of Jak2 and the modulation of oncogenic Stat3 by Jak2 inhibitors have spurred a great interest in the inhibition of the Jak2/Stat pathway in oncology. In this Letter, we communicate the discovery of novel inhibitors of the Jak2/Stat5 axis, the N-(1H-pyrazol-3-yl)pyrimidin-2-amino derivatives. The rationale, synthesis and biological evaluation of these derivatives are reported. Two lead analogs from this series, 6 and 9, displayed prolonged residence time on Jak2, at enzymatic level. Although 6 and 9 exhibited moderate selectivity in a selected kinase panel, we chose to test these inhibitors in vivo as a consequence to their long residence time. However, extended inhibition of Jak2 due to the long residence time, in the form of inhibiting phosphorylation of downstream Stat5, was not recapitulated in an in vivo setting. (c) 2013 Elsevier Ltd. All rights reserved.
• WO2008/117050
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors
  作者：Stephanos Ioannidis、Michelle L. Lamb、Audrey M. Davies、Lynsie Almeida、Mei Su、Geraldine Bebernitz、Minwei Ye、Kirsten Bell、Marat Alimzhanov、Michael Zinda

  DOI：10.1016/j.bmcl.2009.10.054

  日期：2009.12

  The design, synthesis and biological evaluation of a series of pyrazol-3-ylamino pyrazines as potent and selective JAK2 kinase inhibitors is reported, along with the pharmacokinetic and pharmacodynamic properties of lead compounds. (C) 2009 Elsevier Ltd. All rights reserved.
• [EN] PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER<br/>[FR] PYRIMIDINES SUBSTITUÉS PAR PYRAZOLYLE-AMINO ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2008132502A1

  公开（公告）日：2008-11-06

  [EN] The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.
  [FR] La présente invention porte sur des composés de Formule (I) et sur leurs compositions pharmaceutiques, ainsi que sur leurs procédés d'utilisation. Ces composés fournissent un traitement pour des troubles myéloprolifératifs et le cancer.